The selective cyclooxygenase‐2 inhibitor SC‐236 reduces liver fibrosis by mechanisms involving non‐parenchymal cell apoptosis and PPARγ activation
- 3 May 2005
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 19 (9), 1120-1122
- https://doi.org/10.1096/fj.04-2753fje
Abstract
The importance of inflammation in initiating the sequence of events that lead to liver fibrosis is increasingly recognized. In this study, we tested the effects of SC-236, a selective cyclooxygenase (COX)-2 inhibitor, in rats with carbon tetrachloride (CCl4)-induced liver fibrosis. Livers from CCl4-treated rats showed increased COX-2 expression and 15-deoxy-prostaglandin (PG)J2 (15d-PGJ2) formation, as well as decreased peroxisome proliferator-activated receptor (PPAR)gamma expression. In these animals, SC-236 reduced liver fibrosis as revealed by histological analysis and by a reduction in hepatic hydroxyproline levels, metalloproteinase-2 activity, and alpha-smooth muscle actin expression. Interestingly, SC-236 normalized 15d-PGJ2 levels and restored PPARgamma expression in the liver of CCl4-treated rats. In isolated hepatic stellate cells (HSCs)--the major player in liver fibrogenesis--and Kupffer cells--the cell type primarily responsible for increased hepatic COX-2-SC-236 exhibited remarkable pro-apoptotic and growth inhibitory properties. Of interest, SC-236 decreased HSC viability to a similar extent than the PPARgamma ligand rosiglitazone. Moreover, SC-236 significantly induced PPARgamma expression in HSCs and acted as a potent PPARgamma agonist in a luciferase-reporter trans-activation assay. These data indicate that, by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation, the selective COX-2 inhibitor SC-236 might have therapeutic potential for prevention of liver fibrosis.Keywords
Funding Information
- Ministerio de Ciencia y Tecnología (03/0586)
- Instituto de Salud Carlos III (C03/02)
This publication has 50 references indexed in Scilit:
- Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implicationsNature Clinical Practice Gastroenterology & Hepatology, 2004
- Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteinsGut, 2004
- Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosisJournal of Clinical Pathology, 2004
- Current management of alcoholic liver diseaseAlimentary Pharmacology & Therapeutics, 2004
- Cyclooxygenase-2 BiologyCurrent Pharmaceutical Design, 2003
- Prostaglandins and other cyclooxygenase-dependent arachidonic acid metabolites and the kidney in liver diseaseProstaglandins & Other Lipid Mediators, 2003
- New aspects of hepatic fibrosisJournal of Hepatology, 2000
- CYCLOOXYGENASES 1 AND 2Annual Review of Pharmacology and Toxicology, 1998
- Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the ratHepatology, 1997
- Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in ratsCarcinogenesis: Integrative Cancer Research, 1996